LuciEntre 200mg, Entrectinib Capsules

LuciEntre 200mg is a targeted therapeutic medication that contains the potent oral tyrosine kinase inhibitor (TKI) entrectinib. Non-small cell lung cancer (NSCLC) and other solid tumor forms that test positive for particular genetic abnormalities are its main uses. By blocking abnormal proteins that fuel cancer cell growth, LuciEntre offers a personalized and effective approach to cancer treatment.

What is LuciEntre 200mg (Entrectinib)?

LuciEntre 200mg is a prescription anticancer drug developed for the treatment of cancers that harbor ROS1 or NTRK gene fusions. These are genetic changes that cause cancer cells to develop out of control. Entrectinib is intended to stop the spread of cancer by blocking the action of these gene fusions.

It is particularly effective in treating:

• ROS1-positive NSCLC
• NTRK fusion-positive solid tumors (regardless of the tumor’s origin)

How it Works / Mechanism of Action

Several tyrosine kinases are targeted and inhibited by entrectinib:

• ROS1 (c-ros oncogene 1)
• NTRK1/2/3 (neurotrophic tyrosine receptor kinase)
• ALK (anaplastic lymphoma kinase)
• These kinases are essential for cell survival, proliferation, and signaling. When mutated or abnormally fused with other genes, they drive malignant growth. Entrectinib binds to the ATP-binding site of these kinases, blocking their function and leading to cancer cell death or reduced tumor growth.
• Notably, Entrectinib has the ability to cross the blood-brain barrier, offering effectiveness even in cancers with brain metastases.

How to Use / Indications

LuciEntre 200mg is indicated for:

• Patients whose tumors show the ROS1 gene fusion are said to have ROS1-positive metastatic non-small cell lung cancer (NSCLC).
• NTRK fusion-positive solid tumors – including rare or treatment-resistant cancers in adult and pediatric patients over 12 years, where surgical resection is not feasible or standard treatments have failed.
• Molecular testing is essential before initiating therapy to confirm ROS1 or NTRK gene fusions.

How to Take / Dosage

Standard Dosage:

• Adults: LuciEntre is typically administered 600 mg orally once daily.
• For LuciEntre 200mg tablets, this equates to six tablets taken together once daily.
• Administration Guidelines:
• Take at the same time each day, with or without food.
• Swallow tablets whole; do not crush or split.
• Avoid grapefruit or grapefruit juice, which can increase drug levels and side effects.

Other Dosage Information

Pediatric Use:

• For patients ≥12 years, the dosage may vary based on body surface area (BSA).
• Pediatric dosing requires careful adjustment by an oncologist.

Dose Adjustments:

• In case of adverse reactions, hepatic impairment, or drug interactions, dose reductions to 400 mg or 200 mg once daily may be considered.

Side Effects

Like all cancer therapies, LuciEntre 200mg can cause side effects, though not everyone experiences them.

Common Side Effects:

• Fatigue
• Constipation
• Dizziness
• Altered sense of taste (dysgeusia)
• Nausea or vomiting
• Weight gain
• Edema (swelling)
• Cognitive effects (e.g., confusion)

Serious Side Effects:

• Congestive heart failure
• QT interval prolongation (heart rhythm problem)
• Central nervous system effects (hallucinations, memory issues)
• Liver enzyme elevation
• Fractures
• Vision disorders
• Monitoring: Patients should undergo regular liver function tests, cardiac monitoring (ECG), and neurological assessments throughout treatment.

Storage

• Store at room temperature between 20°C to 25°C (68°F to 77°F).
• Keep in the original container, away from moisture and light.
• Do not refrigerate or freeze.
• Keep out of reach of children and pets.

Benefits

• Targeted therapy minimizes harm to healthy cells by focusing on tumors that have ROS1 or NTRK fusions.
• Effective against brain metastases: Crosses the blood-brain barrier.
• Tumor-agnostic therapy: NTRK-positive solid tumors can be treated regardless of the tumor’s location.
• Oral administration: Convenient dosing, no hospital infusion required.
• Rapid response: Patients often show tumor shrinkage within weeks.

Prescription

LuciEntre 200mg requires a doctor’s prescription and should be prescribed by an oncologist experienced in treating genetically defined cancers. Genetic testing (biomarker testing) must confirm ROS1 or NTRK gene fusion positivity before initiation.

Interactions

Since the CYP3A4 enzyme is the primary metabolizer of entrectinib, interactions with other medications that are also metabolized by this enzyme may arise.

Drug Reactions:

• Potent CYP3A4 inhibitors, such as itraconazole and ketoconazole: may raise the levels of entrectinib.
• Strong CYP3A4 inducers, such as phenytoin and rifampin, may reduce effectiveness.
• QT-prolonging drugs: Risk of heart rhythm issues.
• CNS depressants: May enhance cognitive side effects.

Always inform your doctor about all current medications, including herbal supplements.

FAQs

Can LuciEntre 200mg cure cancer?

No, it is not a cure, but it can significantly control tumor growth and improve survival and quality of life.

Is genetic testing mandatory before using LuciEntre?

Yes, ROS1 or NTRK gene fusion must be confirmed via molecular diagnostics.

Can children take LuciEntre?

Yes, for patients aged 12+ with NTRK-positive tumors under medical guidance.

Are there heart-related side effects?

Yes, it may cause QT prolongation—regular ECG monitoring is advised.

Conclusion

LuciEntre 200mg (Entrectinib) is a revolutionary advancement in precision oncology, offering hope to patients with rare genetic mutations across multiple cancer types. With its ability to precisely target tumor-specific alterations, cross the blood-brain barrier, and deliver effective results even in resistant cancers, it represents a new era of personalized treatment. However, due to potential side effects and interactions, its use must be carefully supervised by oncology professionals, with regular monitoring and patient education being crucial for optimal outcomes.